Gan & Lee 甘李药业
26 significant filings since 30 May 2026: 17 on equity incentive, 3 on buyback and 2 on pledge released, and 3 other kinds. The latest, on 27 Aug 2026: 关于公司持股5%以上股东部分股份解押的公告.
自 30 May 2026 起有 26 份重大公告：equity incentive 17 份、buyback 3 份、pledge released 2 份，另有 3 类。最新一份（27 Aug 2026）：关于公司持股5%以上股东部分股份解押的公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥75.94 · Low 最低 ¥68.78 · −1.50% on the previous close of ¥74.56The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 长城国瑞证券 | 胡晨曦 | Buy 买入 | 31 Aug 2026 | 3 | — |
| 国金证券 | 甘坛焕,马居东 | Buy 买入 | 26 Aug 2026 | 3 | — |
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 1 May 2026 | 1 | — |
| 西南证券 | 杜向阳,雷瑞 | Unrated | 29 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 8 reports. 每行为该券商近十二个月的最新研报；8 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。